Citigroup maintains its Buy rating on Spectranetics SPNC and increases its price target by $2 to $11 on positive ISR data from PATENT trial.
Citigroup says, "This morning (2/2), SPNC announced positive 6-month interim data from the German PATENT trial, which is evaluating SPNC's laser atherectomy catheter for in-stent restenosis (ISR) in the femoropopliteal artery in the leg. ... Based on the company's continued positive progress, we are increasing our target to $11 (from $9) based on an increased 3.0x P/S multiple (from 2.5x) on our unchanged 2012 sales of $133M average with our $10 DCF."
SPNC closed at $8.31 a share on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in